4.8 Article

FAM222A encodes a protein which accumulates in plaques in Alzheimer's disease

Journal

NATURE COMMUNICATIONS
Volume 11, Issue 1, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-13962-0

Keywords

-

Funding

  1. US National Institutes of Health [RF1AG056320]
  2. US Alzheimer's Association [AARG-17-499682]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  4. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. AbbVie
  8. Alzheimer's Association
  9. Alzheimer's Drug Discovery Foundation
  10. Araclon Biotech
  11. BioClinica, Inc.
  12. Biogen
  13. Bristol-Myers Squibb Company
  14. CereSpir, Inc.
  15. Cogstate
  16. Eisai Inc.
  17. Elan Pharmaceuticals, Inc.
  18. Eli Lilly and Company
  19. EuroImmun
  20. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  25. Johnson & Johnson Pharmaceutical Research & Development LLC.
  26. Lumosity
  27. Lundbeck
  28. Merck Co., Inc.
  29. Meso Scale Diagnostics, LLC.
  30. NeuroRx Research
  31. Neurotrack Technologies
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Piramal Imaging
  35. Servier
  36. Takeda Pharmaceutical Company
  37. Transition Therapeutics
  38. Canadian Institutes of Health Research

Ask authors/readers for more resources

Alzheimer's disease (AD) is characterized by amyloid plaques and progressive cerebral atrophy. Here, we report FAM222A as a putative brain atrophy susceptibility gene. Our cross-phenotype association analysis of imaging genetics indicates a potential link between FAM222A and AD-related regional brain atrophy. The protein encoded by FAM222A is predominantly expressed in the CNS and is increased in brains of patients with AD and in an AD mouse model. It accumulates within amyloid deposits, physically interacts with amyloid-beta (A beta) via its N-terminal A beta binding domain, and facilitates A beta aggregation. Intracerebroventricular infusion or forced expression of this protein exacerbates neuroinflammation and cognitive dysfunction in an AD mouse model whereas ablation of this protein suppresses the formation of amyloid deposits, neuroinflammation and cognitive deficits in the AD mouse model. Our data support the pathological relevance of protein encoded by FAM222A in AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available